Thin
1 / 1
Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog with a potency approximately 30–150 times that of natural GnRH. As a GnRH agonist, it initially and briefly stimulates the pituitary gland to release gonadotropins (the "flare-up" effect). Subsequently, through sustained agonistic action, it leads to pituitary desensitization and downregulation of GnRH receptors, thereby inhibiting the secretion of gonadotropins (LH, FSH) and ultimately suppressing the production of sex steroid hormones.
Dulaglutide is a long‑acting glucagon‑like peptide‑1 (GLP‑1) receptor agonist. It mimics the action of endogenous GLP‑1, stimulating glucose‑dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety. These effects collectively contribute to improved glycemic control, reduced postprandial glucose levels, and weight management support in research models.
For research purposes, dulaglutide dosing is typically based on model specification (in vitro or in vivo) and experimental design. In preclinical rodent studies, doses often range from 0.1 mg/kg to 1 mg/kg administered subcutaneously once weekly. For larger animal models, dose adjustments are made according to body weight and pharmacodynamic response. Dulaglutide’s extended half‑life supports once‑weekly dosing in both preclinical and translational studies. Researchers should follow institutional guidelines and safety protocols when handling and dosing.
Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog that has a potency approximately 30–150 times greater than that of natural GnRH.
As a GnRH agonist, it initially stimulates the pituitary gland to release gonadotropins. However, sustained action leads to pituitary desensitization and the downregulation of GnRH receptors, which ultimately inhibits the secretion of gonadotropins (LH, FSH) and sex steroid hormones.
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It functions by mimicking endogenous GLP-1, which stimulates glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety.
In research models, the effects of Dulaglutide collectively contribute to improved glycemic control, reduced postprandial glucose levels, and support for weight management.
In preclinical rodent studies, the dosage of Dulaglutide typically ranges from 0.1 mg/kg to 1 mg/kg, administered subcutaneously once a week.
Dulaglutide features an extended half-life, which effectively supports a once-weekly dosing schedule in both preclinical and translational research studies.
